Home » Stocks » SANA

Sana Biotechnology, Inc. (SANA)

Stock Price: $23.59 USD -1.61 (-6.39%)
Updated Apr 19, 2021 1:56 PM EDT - Market open
Market Cap 4.34B
Revenue (ttm) n/a
Net Income (ttm) -285.31M
Shares Out 183.81M
EPS (ttm) -1.55
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 19
Last Price $23.59
Previous Close $25.20
Change ($) -1.61
Change (%) -6.39%
Day's Open 24.94
Day's Range 23.04 - 25.48
Day's Volume 138,243
52-Week Range 21.21 - 44.60


Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

– Targeted in vivo gene delivery of a CAR using a CD8-specific fusogen results in tumor eradication – – Hypoimmune CAR T cells protected from innate and adaptive immune cell recognition and result in tu...

1 week ago - GlobeNewsWire

Expects to present data at multiple scientific conferences in 2021

3 weeks ago - GlobeNewsWire

Cell and gene therapy companies are quickly emerging as favorites of venture capital firms, investors and members of Big Pharma, according to a report from the Alliance for Regenerative Medicine.

Other stocks mentioned: BIIB, FATE, GILD, JNJ, ORTX, SGMO
3 weeks ago - GuruFocus

MADISON, Wis. and SEATTLE, March 17, 2021 (GLOBE NEWSWIRE) -- FUJIFILM Cellular Dynamics, Inc., a leading global developer and manufacturer of human induced pluripotent stem cells (iPSC) technologies, a...

1 month ago - GlobeNewsWire

CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...

Other stocks mentioned: AXLA, CDAK, DNLI, EVLO, FHTX, KLDO, MCRB ...
1 month ago - PRNewsWire

SEATTLE, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the closing of its upsized...

2 months ago - GlobeNewsWire

Sana Biotechnology raised $587.

2 months ago - GeekWire

SEATTLE, Feb. 03, 2021 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (Sana) (Nasdaq: SANA), a company focused on creating and delivering engineered cells as medicines, today announced the pricing of its ...

2 months ago - GlobeNewsWire

Sana Biotechnology — the Seattle upstart that's looking to treat a variety of diseases through gene therapy and cell engineering — is generating buzz on Wall…

2 months ago - GeekWire

The Seattle, Wash.-based biotech company says it will raise the funds by offering 15 million shares at $20 to $23 per share.

2 months ago - BioSpace

Sana Biotechnology is following the Moderna playbook to a tee: Promise a lot based on very early science, be vague, nab a major VC raise, then gun for an IPO.

3 months ago - FierceBiotech

The Seattle-based gene therapy startup filed with the U.S. Securities and Exchange Commission on Wednesday.

3 months ago - Puget Sound Business Journal

Sana Biotechnology has filed with the U.S. Securities and Exchange Commission to raise up to $150 million in an initial public offering to help support the companyu2019s cell-based therapy discovery and...

3 months ago - BioSpace

Less than three years after it was founded and with no revenue on the books, Sana Biotechnology filed to go public on Wednesday in what would be the latest...

3 months ago - GeekWire

Sana Biotechnology, a preclinical biotech developing engineered cell therapies for multiple indications, filed on Wednesday with the SEC to raise up to $150 million in an initial public offering.

3 months ago - NASDAQ

Sana Biotechnology, Inc. has filed to go public with an IPO on the NASDAQ.

3 months ago - SEC

UC San Francisco scientists have discovered a new way to control the immune system's "natural killer" (NK) cells, a finding with implications for novel cell therapies and tissue implants t...

3 months ago - News-Medical.net

About SANA

Sana Biotechnology was founded on the belief that engineered cells will be one of the most important transformations in medicine over the next several decades. The burden of diseases that can be addressed at their root cause through engineered cells is significant. We view engineered cells as having the potential to be as therapeutically disruptive as biologics to clinical practice. Our long-term aspirations are to be able to control or modify any gene in the body, to replace any cell that is damaged or missing, and to markedly improve access t... [Read more...]

IPO Date
Feb 4, 2021
Steven D. Harr, M.D.
Stock Exchange
Ticker Symbol
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for SANA is 41.33, which is an increase of 75.20% from the latest price.

Price Target
(75.20% upside)